Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
- PMID: 32290280
- PMCID: PMC7238255
- DOI: 10.3390/pharmaceutics12040342
Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
Abstract
Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using 15N-ssNMR (15N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms.
Keywords: X-ray diffraction; co-crystal; polymorphism; salt; ssNMR; tenofovir alafenamide fumarate.
Conflict of interest statement
The authors declare no conflict of interest.
Figures










Similar articles
-
On the Single-Crystal Structure of Tenofovir Alafenamide Mono-Fumarate: A Metastable Phase Featuring a Mixture of Co-Crystal and Salt.Int J Mol Sci. 2020 Dec 3;21(23):9213. doi: 10.3390/ijms21239213. Int J Mol Sci. 2020. PMID: 33287166 Free PMC article.
-
Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate.J Pharm Biomed Anal. 2016 Nov 30;131:146-155. doi: 10.1016/j.jpba.2016.08.022. Epub 2016 Aug 26. J Pharm Biomed Anal. 2016. PMID: 27589032
-
Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient.Ther Adv Infect Dis. 2018 Jul 10;5(5):91-95. doi: 10.1177/2049936118785497. eCollection 2018 Sep. Ther Adv Infect Dis. 2018. PMID: 30224952 Free PMC article.
-
Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence.Therap Adv Gastroenterol. 2018 Jul 16;11:1756284818786108. doi: 10.1177/1756284818786108. eCollection 2018. Therap Adv Gastroenterol. 2018. PMID: 30034532 Free PMC article. Review.
-
Emtricitabine + tenofovir alafenamide for the treatment of HIV.Expert Opin Pharmacother. 2017 Mar;18(4):427-432. doi: 10.1080/14656566.2017.1288720. Epub 2017 Feb 8. Expert Opin Pharmacother. 2017. PMID: 28151023 Review.
Cited by
-
On the Single-Crystal Structure of Tenofovir Alafenamide Mono-Fumarate: A Metastable Phase Featuring a Mixture of Co-Crystal and Salt.Int J Mol Sci. 2020 Dec 3;21(23):9213. doi: 10.3390/ijms21239213. Int J Mol Sci. 2020. PMID: 33287166 Free PMC article.
-
Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue.Pharmaceutics. 2022 Aug 6;14(8):1641. doi: 10.3390/pharmaceutics14081641. Pharmaceutics. 2022. PMID: 36015269 Free PMC article.
References
-
- The Top 10 Causes of death. [(accessed on 12 March 2020)]; Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
-
- Global Factsheets 2018 HIV and AIDS Estimates. [(accessed on 12 March 2020)]; Available online: http://aidsinfo.unaids.org/
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous